Combination therapy with M13 phage targeting Fusobacterium nucleatum (Fn) and silver nanoparticles can effectively inhibit the development of CRC by remodeling Fn, reducing immunosuppressive cells (MDSCs), and activating antigen-presenting cells (APCs) to remodel the tumor immune microenvironment (Dong et al., 2020). The gene discussed is FN1; the disease is neoplasm.